Diffuse Lung Disease
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are associated with irreversible loss of lung function with a poor prognosis. Now, a recent phase 2 trial of admilparant, a […]
-
Newest Bridging Specialties program focuses on team-based care in PH-ILD
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages collaboration across disciplines and provides assets designed for practical use.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Delving deeper into the molecular genetics of idiopathic pulmonary fibrosis
William Whalen II, MD, MS, reflects on his experience as a recipient of the 2023 CHEST Research Grant in Pulmonary Fibrosis and how it has affected his professional trajectory.
-
TETON trials could herald multimodal approach to IPF
Steven Nathan, MD, said the addition of inhaled treprostinil would offer a novel approach that would allow clinicians to target the disease on two fronts.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.
-
COVID-19 immune patterns offer hope for future IPF treatment
Jose D. Herazo-Maya, MD, and colleagues are investigating a mechanism of T-cell suppression that may contribute to the development of a treatment for pulmonary fibrosis.
-
Navigating new ACR/CHEST guidelines for screening, monitoring, and treatment of SARD-ILD
Authors Jose R. Castellanos, MD; Anthony J. Esposito, MD; and Caroline Zhao, MD, discuss key strategies, including early screening with pulmonary function tests and high-resolution chest tomography, cautious glucocorticoid use, and personalized steroid-sparing treatment.
-
Improving ILD diagnosis in primary care settings
Interstitial lung diseases (ILDs), with their many ubiquitous symptoms, are often hard to diagnose in patients. That’s why Amirahwaty Abdullah, MBBS, and Kavitha Selvan, MD, see value in educating clinicians […]
-
CHEST grant winners to study health inequities related to air pollution, medication nonadherence, and more
In 2023, CHEST awarded $300,000 in clinical research and community impact grants to 15 individuals. Grant recipients are recognized for their scientifically meritorious achievements, with rigorous metrics to track their […]
